Last updated: August 14, 2026
Diflucan, Pfizer’s brand for fluconazole, moved from blockbuster antifungal to mature generic medicine after U.S. patent protection ended around 2000. Pfizer’s worldwide Diflucan revenue reached approximately $1 billion around the peak period, then declined as generic fluconazole entered the U.S. and other markets. The product remains FDA-approved and clinically important, but its commercial value now resides mainly in high-volume, low-price generic supply rather than branded pricing power.
What is Diflucan and how is fluconazole used?
Diflucan is the brand name for fluconazole, a triazole antifungal administered orally and intravenously. Pfizer originally developed and commercialized the product.
| Attribute |
Diflucan |
| Active ingredient |
Fluconazole |
| Drug class |
Triazole antifungal |
| Originator |
Pfizer |
| U.S. approval |
1990 |
| Dosage forms |
Capsules, oral suspension, intravenous injection |
| Primary uses |
Vaginal candidiasis, oropharyngeal and esophageal candidiasis, systemic Candida infections, cryptococcal meningitis |
| U.S. status |
Mature branded product with generic competition |
| Biosimilar exposure |
None; fluconazole is a small-molecule drug |
| Main commercial competitors |
Generic fluconazole manufacturers and other antifungal therapies |
The product inhibits fungal cytochrome P450-dependent sterol synthesis, principally through inhibition of lanosterol 14-alpha-demethylase. Its oral bioavailability, broad distribution, and once-daily dosing supported rapid adoption in hospitals and outpatient care.[1]
When did Diflucan lose exclusivity?
Diflucan lost its principal U.S. composition-of-matter protection around 2000. Generic fluconazole approvals followed, ending Pfizer’s ability to maintain monopoly pricing in the U.S. market.
Diflucan exclusivity timeline
| Event |
Approximate timing |
Commercial effect |
| U.S. FDA approval |
1990 |
Launch of branded fluconazole |
| Initial commercial expansion |
1990s |
Rapid uptake across hospital and outpatient indications |
| Principal U.S. patent expiry |
Around 2000 |
ANDA-based generic entry became possible |
| Generic competition |
Early 2000s |
Sharp pressure on U.S. price and volume |
| Mature generic market |
2010s-present |
High unit volume with low average selling prices |
The core U.S. patent was U.S. Patent No. 4,404,216, covering fluconazole-related chemical matter. The patent was filed before the Hatch-Waxman framework’s modern patent-term rules and expired after the applicable term, with commercial protection ending around 2000.[2]
Any remaining patent rights would have been limited to later formulations, manufacturing processes, or specific uses rather than the basic fluconazole molecule. Those rights did not preserve broad product exclusivity.
What patents protect Diflucan today?
No broad, commercially meaningful U.S. patent barrier protects the fluconazole molecule today. The central patent estate expired long ago, and generic manufacturers have supplied fluconazole for more than two decades.
Composition patents
The principal composition patent protected the fluconazole chemical entity and expired around 2000. Because the molecule is now off patent, generic manufacturers can produce the same active ingredient subject to FDA quality, bioequivalence, manufacturing, and labeling requirements.
Formulation patents
Diflucan has been marketed in several dosage forms, including capsules, oral suspension, and intravenous injection. Formulation-specific patent rights, if any, have not prevented broad generic availability. Generic products compete across the same basic dosage forms.
The commercial distinction is therefore manufacturing capability rather than formulation exclusivity. Injectable fluconazole requires sterile manufacturing and more demanding quality controls than oral capsules or tablets, but those requirements are regulatory barriers rather than patent monopolies.
Method-of-use patents
Fluconazole has multiple labeled uses. The core indications are old and generally do not support current exclusivity. Later method-of-use claims could have had narrower relevance, but they did not block generic fluconazole for the principal indications.
What is the Orange Book status of Diflucan?
Diflucan is an FDA-approved small-molecule drug with generic equivalents listed through the Abbreviated New Drug Application pathway. Its commercial profile is consistent with a mature product whose main composition patent has expired.
The Orange Book identifies approved drug products, therapeutic equivalence ratings, and applicable patent or exclusivity information. For a product such as Diflucan, the key commercial fact is that generic fluconazole products have been approved and marketed for years. FDA approval of generic fluconazole generally depends on demonstrating pharmaceutical equivalence and bioequivalence rather than repeating Pfizer’s full clinical development program.[3]
There is no biosimilar pathway for Diflucan. Biosimilars apply to biological products, while fluconazole is a chemically synthesized small molecule.
How did generic entry change Diflucan’s financial trajectory?
Generic entry changed Diflucan from a high-margin branded medicine into a mature product with declining branded revenue and reduced pricing power.
Pfizer reported Diflucan worldwide sales at approximately $1 billion around the beginning of the 2000s. After U.S. patent expiry, the company reported declining performance as generic competition affected U.S. sales and pricing. Pfizer’s annual-report disclosures during the period described patent expiry and generic competition as direct drivers of erosion.[4]
Financial trajectory
| Period |
Financial position |
Main driver |
| 1990s |
Rapid growth and high-margin branded sales |
Broad clinical adoption and limited competition |
| Around 2000 |
Approximately $1 billion in worldwide sales |
Mature global brand before full generic erosion |
| Early 2000s |
Declining sales |
U.S. generic entry and price compression |
| 2010s |
Mature, lower-value brand |
Generic substitution and loss of premium pricing |
| 2020s |
Limited standalone strategic relevance to Pfizer |
Low-cost generic market and fragmented supply |
The exact current financial contribution of Diflucan to Pfizer cannot be isolated reliably from Pfizer’s public reporting because Pfizer does not consistently report the brand as a separate current revenue line. The brand’s economic value is now materially smaller than during its blockbuster period.
What is the current fluconazole market structure?
The current market is fragmented across generic manufacturers, contract manufacturers, hospital suppliers, and regional pharmaceutical companies. Competition is based on price, supply continuity, regulatory compliance, and access to active pharmaceutical ingredient capacity.
Oral fluconazole
Oral capsules, tablets, and suspension are highly commoditized. The principal commercial risks are:
- Low average selling prices.
- Substitution by therapeutically equivalent generics.
- Pharmacy and hospital purchasing pressure.
- Periodic supply disruption.
- Limited ability to differentiate the active ingredient.
Retail and institutional buyers generally treat generic fluconazole as interchangeable where products carry appropriate FDA therapeutic-equivalence ratings.
Intravenous fluconazole
The intravenous segment has higher manufacturing complexity because products require sterile filling, validated aseptic processes, container-closure controls, and robust quality systems. This creates a higher operational barrier than oral dosage forms.
The barrier is not equivalent to patent exclusivity. A capable generic manufacturer can compete if it satisfies FDA requirements and maintains reliable supply.
International markets
Outside the United States, fluconazole is widely available from national and regional manufacturers. Market dynamics vary by country because of:
- National reimbursement policies.
- Tender-based hospital procurement.
- Local registration requirements.
- Import controls.
- Reference-pricing systems.
- National patent laws and historical patent terms.
In many emerging markets, fluconazole is sold under numerous local brands and generic labels. Pfizer’s Diflucan brand retains recognition in some markets, but brand recognition does not generally translate into U.S.-style exclusivity or premium pricing.
Which companies compete with Diflucan?
The principal competitors are generic fluconazole suppliers rather than branded pharmaceutical innovators.
Generic competitors
U.S. fluconazole products have historically been marketed by manufacturers such as:
- Teva Pharmaceuticals.
- Sandoz.
- Viatris and legacy Mylan operations.
- Hikma Pharmaceuticals.
- Dr. Reddy’s Laboratories.
- Cipla.
- Amneal Pharmaceuticals.
- Rising Pharmaceuticals.
- Other approved ANDA holders and contract manufacturers.
The identity and active status of suppliers change over time because products may be discontinued, transferred, or temporarily unavailable. The market remains competitive because the active ingredient is off patent and multiple approved sources exist.
Therapeutic competitors
Fluconazole competes clinically with other antifungal agents, including:
- Itraconazole.
- Voriconazole.
- Posaconazole.
- Isavuconazole.
- Amphotericin B.
- Echinocandins such as micafungin, caspofungin, and anidulafungin.
These products do not compete uniformly across indications. Fluconazole remains attractive in susceptible infections because of its oral formulation, established safety profile, broad clinical familiarity, and low cost. Newer agents can command higher prices in resistant infections, invasive disease, or settings requiring broader antifungal coverage.
Are there Paragraph IV challenges or Diflucan patent litigation?
Paragraph IV litigation was commercially relevant around the period when generic manufacturers sought U.S. approval before or near expiry of Pfizer’s principal fluconazole patent. Once the core patent expired and multiple generic products entered the market, litigation ceased to be a central barrier to commercial supply.
The current risk profile is different:
| Litigation issue |
Current relevance |
| Challenge to the core fluconazole patent |
Minimal; principal patent expired |
| Paragraph IV launch risk |
Historical rather than a current branded threat |
| Formulation patent litigation |
Narrow and unlikely to block the molecule |
| Patent settlement risk |
Low for the mature product |
| Manufacturing litigation |
Possible, but generally company-specific |
| Product liability or quality litigation |
More relevant than exclusivity litigation |
No major current patent dispute is required for generic fluconazole commercialization. The primary legal risks concern manufacturing quality, regulatory compliance, labeling, supply contracts, and product liability.
What licensing deals affect Diflucan?
Pfizer’s historical commercialization of Diflucan depended on its own development and global commercial infrastructure. The mature fluconazole market is now characterized by generic manufacturing and distribution arrangements rather than a major active licensing contest over the molecule.
Generic companies may use contract manufacturing, API supply agreements, regional distribution arrangements, or local licensing structures. These transactions affect supply and market share, but they do not restore exclusivity to the Diflucan brand.
No publicly reported current licensing transaction changes the fundamental commercial position: fluconazole is an off-patent generic medicine, and Pfizer’s brand competes mainly through recognition, regulatory history, and distribution.
How strong is the Diflucan patent estate?
The patent estate is weak from a market-exclusion standpoint and strong only as historical intellectual property.
| Dimension |
Assessment |
| Core composition protection |
Expired |
| Current U.S. exclusivity |
None of commercial significance |
| Formulation protection |
Limited or non-blocking |
| Method-of-use protection |
Narrow and largely historical |
| Manufacturing barriers |
Moderate for sterile products |
| Generic substitution risk |
High |
| Biosimilar risk |
Not applicable |
| Branded pricing power |
Low |
| Litigation leverage |
Low |
The remaining competitive advantage is operational. Companies with validated sterile facilities, reliable API sourcing, and strong regulatory records can compete more effectively than companies relying on patent protection.
What generic launch scenarios exist for Diflucan?
The most likely commercial scenario is continued erosion of branded share combined with stable or rising generic unit demand.
Scenario 1: Continued commodity pricing
Generic suppliers maintain broad availability, and purchasing organizations continue to select the lowest-cost therapeutically equivalent products. Pfizer’s branded revenue remains limited.
Scenario 2: Supply-constrained price recovery
Manufacturing interruptions, API shortages, or quality-related recalls reduce the number of active suppliers. Prices may rise temporarily, particularly for injectable presentations. This would be a supply event, not a patent-driven recovery.
Scenario 3: Clinical substitution
Invasive fungal disease, resistance, or changes in treatment guidelines may shift some demand toward newer triazoles or echinocandins. This would affect fluconazole volume mainly in high-acuity settings, while low-cost outpatient use remains resilient.
What is the revenue exposure for Pfizer and generic manufacturers?
Pfizer’s revenue exposure is now modest relative to its major patented and recently launched medicines. The company’s historical Diflucan revenue was significant, but the product’s contribution declined after generic entry and is not separately prominent in current corporate reporting.
Generic manufacturers face a different exposure profile. Fluconazole can generate meaningful volume but generally limited revenue per unit. Profitability depends on:
- Manufacturing scale.
- API procurement.
- Product availability.
- Contract pricing.
- Hospital tenders.
- Regulatory compliance.
- Ability to maintain sterile production for injection products.
For investors, fluconazole is primarily a volume and supply-chain asset, not a patent-protected growth asset.
Key Takeaways
- Diflucan is Pfizer’s branded fluconazole product, first approved in the U.S. in 1990.
- The core U.S. patent expired around 2000.
- Pfizer’s worldwide Diflucan sales reached approximately $1 billion around the peak period.
- Generic entry sharply reduced branded pricing power and U.S. revenue.
- Current commercial competition is dominated by generic manufacturers.
- There is no biosimilar risk because fluconazole is a small-molecule drug.
- Oral fluconazole is highly commoditized; intravenous fluconazole has higher sterile-manufacturing barriers.
- Current value depends on supply reliability, regulatory compliance, and procurement economics rather than patent exclusivity.
- No active patent estate is likely to block broad generic fluconazole commercialization.
- Pfizer’s current standalone revenue exposure is limited and not consistently reported separately.
FAQs
Is Diflucan still sold by Pfizer?
Yes. Pfizer’s Diflucan brand remains an FDA-approved fluconazole product, but it competes with numerous generic versions and no longer has broad market exclusivity.
What is the generic name for Diflucan?
The generic name is fluconazole. It is available in oral and intravenous formulations from multiple manufacturers.
Can generic fluconazole replace Diflucan?
In approved strengths and dosage forms, FDA-rated therapeutically equivalent generic products can generally substitute for Diflucan under applicable pharmacy and institutional rules.
Does Diflucan have pediatric exclusivity today?
No current pediatric exclusivity period provides meaningful market protection for Diflucan. Any historical exclusivity associated with development programs has expired.
Is fluconazole manufacturing commercially attractive?
It can be attractive for high-volume manufacturers with low production costs and reliable quality systems. Margins are constrained for oral products, while sterile injectable production can offer better economics but requires greater capital, compliance, and operational capability.
References
- U.S. Food and Drug Administration. (2024). Diflucan (fluconazole) prescribing information. https://www.accessdata.fda.gov
- United States Patent and Trademark Office. (1983). U.S. Patent No. 4,404,216: Alpha-(2,4-difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol. https://patents.google.com
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
- Pfizer Inc. (2001-2005). Annual reports. https://www.pfizer.com/investors/financial-information/annual-reportsproxy-statements
